Niosomal Formulation For Co-Administration of Hydrophobic Anticancer Drugs Into Mcf-7 Cancer Cells

Introduction: designing and developing drug delivery systems has received tremendous attention during the last decade. the treatment of cancer cells is a complicated process due to the existence of different biological pathways. therefore, the co-delivery of different drugs could have a synergic effect on the treatment process. materials and methods: in this study, different types of span (20, 60, 80) and cholesterol were utilized to formulate tamoxifen/curcumin co-loaded niosomes as a drug carrier system for breast cancer chemotherapy. niosome characterization was performed through a set of instrument analysis techniques including scanning electron microscopy (sem) and dynamic light scattering. release behavior was studied by dialysis method at (ph = 5, 7.4). the stability was monitored during two months storage at two temperatures (4 and 25 °c). cytotoxicity activity of the best niosomal formulation were assessed on mcf-7 cells, using mtt assay. results: the optimal niosomal formulation with span 80 and lipid-to-drug molar ratio of 20 was selected, with maximum encapsulation of both drugs and minimum size. drug release behavior at physiological ph (7.4) (with significant drug release under acidic conditions (ph = 5) and storage stability of up to 2 weeks with little change in drug efficacy and measurement makes it a proper candidate for breast cancer treatment. conclusion: finally, the results of this study showed the importance of creating highly biocompatible formulations, allowing the simultaneous transfer of two drugs with controlled release to cancer cells which could improve the chemotherapy process with the synergistic effect of the two drugs.